Non-Opioid Pain Management Solutions in Provo, UT

What I’d check before adding non opioid pain management here

Joe Bradley will tell you the same thing he tells his own staff: epidemiology first, then MAC, then SKU. CDC PLACES (2023, crude) estimates 6.1% of adults in Provo have diagnosed diabetes — 5.9 points below the U.S. 12% figure. 12.6% of adults 18–64 here currently lack health insurance (CDC PLACES ACCESS2, 2023). Cash-pay PRP and Medicare CTPs cannot share one consent script. Then we pick non opioid pain management against that mix.

Cash PRP and Medicare CTPs in the same hallway

• Adult arthritis here is 14.1% (CDC PLACES 2023, crude). That is the joint-pain backdrop for PRP and orthobiologics — not a promise that every arthritic knee is a candidate. 12.6% of adults 18–64 here currently lack health insurance (CDC PLACES ACCESS2, 2023). Cash-pay PRP and Medicare CTPs cannot share one consent script. PRP is autologous and not a 361 allograft, but “patient prefers regenerative” is still not medical necessity in Utah.
• Staff turnover in a city under 250k makes “we trained them last year” a weak control. HCT/P handling, centrifuge SOPs, and wound-photo standards need a named owner in the practice, not a one-time in-service.
• Chronic wounds that stall past 30 days are the typical entry point for cellular/tissue products. CDC diabetes prevalence is the epidemiologic backdrop; JF coverage rules are the billing backdrop. Both have to be true on the same chart.

Payer geography for Provo, UT

JF reviewers still want serial wound measurements and conservative-care history before CTPs, whether diabetes in Provo is 6.1% or not. PLACES is planning data. The LCD is the claim.

Staff, tickets, photos — in that order